# N4 Pharma provides Positive Update on Nuvec® oral delivery research

- Link: https://www.directorstalkinterviews.com/n4-pharma-provides-positive-update-on-nuvec%c2%ae-oral-delivery-research/4121152224
- Published: 2024-04-18T07:22:14+01:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided a further
positive update on its ongoing oral delivery research work.

The Company, through its research program with the University of Queensland, has
undertaken further testing, _in vivo_, to show the successful delivery of a Nuvec
® capsule into the intestine where it has released its plasmid DNA payload to produce
localised protein expression. This work further demonstrates the potential of Nuvec
® as an oral delivery system for multiple nucleotide payloads. 

Specifically, in this experiment an enterically coated capsule containing PEGylated
Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 
and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. 
Protein expression was significantly higher than control (DNA alone and non-PEGylated
DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In
addition, a significantly higher ovalbumin antibody response was measured at day
36 in the PEGylated Nuvec® sample compared to control.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> _“__This work once more clearly shows that Nuvec® has the potential to be developed
> as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential 
> applications such as a vaccination with plasmid DNA or to deliver a local product
> for Irritable Bowel Disease or to treat colonic cancer among many possible examples._
> _“We will continue to scope out the work needed to explore a potential development
> program focusing on a specific oral application and further news on this will 
> be announced when a program is identified. In the meantime, the University of 
> Queensland will continue its work as part of our ARC funded grant with them_.”

Share on: